INTRA-CELLULAR ($NASDAQ:ITCI): Intra-Cellular Therapies, Inc. is a biopharmaceutical company that is focused on developing and commercializing treatments for neuropsychiatric and neurological disorders. The company utilizes a drug discovery platform to develop therapies targeting cellular pathways for a variety of therapeutic areas.
In addition, they have established partnerships with leading pharmaceutical organizations to bring their therapies to market. On August 18, 2023, Intra-Cellular Therapies will be presenting at the Canaccord Genuity 43rd Annual Growth Conference in New York. This conference is an excellent opportunity for the company to showcase their innovative treatments and to engage with potential investors and partners in the industry. Attendees will be able to learn more about the treatments Intra-Cellular Therapies is researching as well as their progress in the development and commercialization process. It is expected that this presentation will provide Intra-Cellular Therapies with an invaluable platform to share their successes and accomplishments as a leading biopharmaceutical company. The Canaccord Genuity 43rd Annual Growth Conference will give the company the opportunity to demonstrate their commitment to bringing innovative treatments to those suffering from neuropsychiatric and neurological disorders. By attending the Canaccord Genuity 43rd Annual Growth Conference, Intra-Cellular Therapies is proving their dedication to advancing treatments for neuropsychiatric and neurological disorders. This is an opportunity that investors, potential partners, and the general public should not miss.
On Monday, Intra-Cellular Therapies, Inc. (ICT) stock opened at $58.9 and closed at $58.9, showing a 0.7% increase from prior closing price of 58.5. The Canaccord Genuity Growth Conference is one of the largest and most influential investor events in the world, hosting hundreds of companies and inviting investors from all across the globe. ICT is looking forward to taking this opportunity to share its advances in the development of drugs that target the intracellular regulatory networks, and to discuss its robust clinical development plans.
Intra-Cellular Therapies is committed to providing innovative treatments for patients suffering from a range of psychiatric and central nervous system disorders. The company’s participation in Canaccord Genuity’s 43rd Annual Growth Conference is an important step in advancing this mission, and provides an opportunity to showcase ICT’s progress to a wide global audience. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Intra-cellular Therapies. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intra-cellular Therapies. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intra-cellular Therapies. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Intra-cellular Therapies are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Intra-cellular Therapies Stock Fair Value
At GoodWhale, we have conducted an analysis of INTRA-CELLULAR THERAPIES‘ fundamentals. After taking into account the company’s financial and operational health, we calculated the intrinsic value of INTRA-CELLULAR THERAPIES shares to be around $163.9 using our proprietary Valuation Line. Currently, INTRA-CELLULAR THERAPIES shares are trading at $58.9, which means that the stock is undervalued by 64.1%. This discrepancy presents an investment opportunity for those who want to capitalize on the mispricing of the stock. More…
Risk Rating Analysis
Star Chart Analysis
The company’s lead product candidate, lumateperone, is in Phase III clinical trials for the treatment of schizophrenia. SCYNEXIS Inc, Invion Ltd, and Shuttle Pharmaceuticals Holdings Inc are all clinical stage biopharmaceutical companies that focus on the development of small molecule drugs for the treatment of neuropsychiatric disorders.
SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of oral and intravenous anti-infective agents to treat patients with serious and life-threatening infections. The company’s lead product, SCY-078, is a novel, first-in-class oral and intravenous agent in clinical development for the treatment of serious fungal infections. The company’s second product, SCY-123, is an oral agent in clinical development for the treatment of bacterial infections, including Clostridium difficile infection.
Invion Ltd is a development stage biopharmaceutical company, which focuses on the treatment of cancer and inflammatory disease. The company was founded in 2003 and is headquartered in Brisbane, Australia.
– Shuttle Pharmaceuticals Holdings Inc ($NASDAQ:SHPH)
Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 25.81M as of 2022. The company has a Return on Equity of 47.66%. Shuttle Pharmaceuticals Holdings Inc is engaged in the research, development, manufacture, and sale of pharmaceutical products. The company’s products include prescription and over-the-counter drugs, as well as nutritional supplements and other health-related products.
Intra-Cellular Therapies, Inc. has recently announced its intention to present at the Canaccord Genuity 43rd Annual Growth Conference. The company is a biopharmaceutical company focused on the discovery and development of small molecule drugs that target intracellular signaling pathways to treat serious neurological and psychiatric disorders. Investors should watch for the company’s presentation as it will provide further insight into its current product pipeline and its potential for future success. Intra-Cellular Therapies has a number of potential therapies in various stages of development, including those targeting neuropsychiatric diseases, glioblastoma, tauopathies and neurodegenerative diseases. Analysts have also noted that the company’s current drug candidates have broad target indications and potential for rapid breakthroughs in treatment.
Additionally, the company’s strong research and development capabilities make it an attractive investment for those looking for long-term growth potential in the drug discovery and development space.